Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled multiple ascending dose study of intravenous BBT001 in chronic spontaneous urticaria
CTR20262419Phase 2Active
- Sponsor
- Bambusa Therapeutics
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BBT001 in chronic idiopathic urticaria (CIU), sponsored by Bambusa Therapeutics. Started Jun 2026; status: active.
02
Drugs
BBT001
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20262419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262419.